吉西他滨联合奥沙利铂治疗化疗无效的淋巴瘤的临床观察

目的:观察吉西他滨联合奥沙利铂治疗化疗无效的淋巴瘤的临床疗效和安全性。方法:60例化疗无效的淋巴瘤患者按随机数字表法均分为对照组和观察组。对照组患者给予吉西他滨1 000 mg/m2,d1、d8静脉滴注30 min;观察组患者在对照组治疗的基础上给予奥沙利铂130 mg/m2,d1静脉滴注2⁶ h。两组患者在治疗同时均给予还原型谷胱甘肽1.2 g静脉滴注,昂丹司琼8mg肌肉注射。21 d为1个疗程,治疗2个疗程后评价疗效、毒性反应及生存率。结果:观察组患者总有效率、6个月生存率显著高于对照组,两组比较差异有统计学意义(P<0.05)。两组患者毒性反应、3个月生存率比较,差异无统计学意义(P>0.05)。结论:吉西他滨联合奥沙利铂治疗化疗无效的淋巴瘤患者较单用吉西他滨疗效更好,安全性亦较好,可提高患者生存率。

Clinical Observation of Gemcitabine Combined with Oxaliplatin in the Treatment of Lymphoma Patients after Failure of Chemotherapy Regimens

OBJECTIVE：To observe clinical efficacy and safety of gemcitabine combined with oxaliplatin（GEMOX）in the treatment of lymphoma patients after failure of chemotherapy regimens. METHODS：60 lymphoma patients after failure of chemotherapy regimens were randomly divided into observation group and control group. Control group was given gemcitabine 1 000 mg/m2 intravenously,d1,d8,for 30 min. Observation group was given oxaliplatin 130 mg/m2 intravenously,d1,for 2-6 h on the basis of control group. Both groups received reduced glutathione 1.2 g intravenously and ondansetron 8 mg intramuscularly. A treatment course lasted for 21 d,and therapeutic efficacy,toxic reaction and survival rate were evaluated after 2 cycles. RESULTS：Total effective rate and 6 months survival rate of observation group were significantly higher than those of control group;there was statistical significance（P〈0.05）. The toxic reaction and 3 months survival rate of both groups had no statistically significant difference（P〉0.05）. CONCLUSIONS：Compared with gemcitabine alone,GEMOX regimen can get a better therapeutic efficacy in lymphoma patients after failure of chemotherapy regimens with acceptable safety and can improve survival rate effectively.